Novel prophylactic and therapeutic vaccine against tuberculosis

作者：Okada Masaji^*; Kita Yoko; Nakajima Toshihiro; Kanamaru Noriko; Hashimoto Satomi; Nagasawa Tetsuji; Kaneda Yasufumi; Yoshida Shigeto; Nishida Yasuko; Nakatani Hitoshi; Takao Kyoko; Kishigami Chie; Inoue Yoshikazu; Matsumoto Makoto; McMurray David N; dela Cruz E C; Tan E V; Abalos R M; Burgos J A; Saunderson Paul; Sakatani Mitsunori

来源：Vaccine, 2009, 27(25-26): 3267-3270.

DOI：10.1016/j.vaccine.2009.01.064

• HSP65 IL-12 DNA vaccine
• Tuberculosis
• Therapeutic effect

We have developed a novel tuberculosis (TB) vaccine: a combination of the DNA vaccines expressing mycobacterial heat shock protein 65 (HSP65) and interleukin 12 (IL-12) delivered by the hemagglutinating virus of Japan (HVJ)-envelope and -liposome (HSP65 IL-12/HVJ). This vaccine provided therapeutic efficacy as well as remarkable protective efficacy via CD8( ) T and CD4( ) T cells in murine models compared with the saline controls, on the basis of CFU of number of multi-drug resistant TB (MDR-TB), and survival of extremely drug resistant TB (XDR-TB) challenged mice. Furthermore, we extended our studies to a cynomolgus monkey model, which is currently the best animal model of human tuberculosis. This vaccine exerted therapeutic efficacy (survival and immune responses) in the TB-infected monkeys. These data indicate that our novel DNA vaccine might be useful against Mycobacterium tuberculosis including XDR-TB and MDR-TB for human therapeutic clinical trials.

• 出版日期2009-5-26